Advanced Solid Tumor Clinical Trials in Ann Arbor, Michigan

10 studies are recruiting for advanced solid tumor in Ann Arbor, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

   This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Michigan Health System, Ann Arbor, Michigan

   Locations

   28 in total

   Run by

   BeOne Medicines

   See if you can join NCT05981703 on ClinicalTrials.gov

2. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Michigan Hospitals, Ann Arbor, Michigan

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

3. Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

   BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Michigan Rogel Cancer Center, Ann Arbor, Michigan

   Locations

   21 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT06635785 on ClinicalTrials.gov

4. Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

   This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose e…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan

   Locations

   8 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT06352359 on ClinicalTrials.gov

5. A Study of YL201 in Patients With Advanced Solid Tumors

   This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohor…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   006, Ann Arbor, Michigan

   Locations

   45 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT05434234 on ClinicalTrials.gov

6. BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

   This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and tolerability of increasing doses of BAL0891 in patients with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Michigan, Ann Arbor, Michigan

   Locations

   17 in total

   Run by

   SillaJen, Inc.

   See if you can join NCT05768932 on ClinicalTrials.gov

7. A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

   This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 to 89

   Site

   University of Michigan Rogel Cancer Center, Ann Arbor, Michigan

   Locations

   57 in total

   Run by

   Eikon Therapeutics

   See if you can join NCT06253130 on ClinicalTrials.gov

8. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

   This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Michigan, Ann Arbor, Michigan

   Locations

   14 in total

   Run by

   Volastra Therapeutics, Inc.

   See if you can join NCT05902988 on ClinicalTrials.gov

9. Study of SGR-3515 In Participants With Advanced Solid Tumors.

   The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Michigan, Ann Arbor, Michigan

   Locations

   14 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT06463340 on ClinicalTrials.gov

10. A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

    This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical …

    Stage

    Phase 2

    Ages

    0 to 25

    Site

    CS Mott Children's Hospital, Ann Arbor, Michigan

    Locations

    35 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT04775485 on ClinicalTrials.gov